The pharmaceutical industry is continuously evolving, with substantial demand for high-efficacy Active Pharmaceutical Ingredients (APIs). Dulaglutide, a GLP-1 receptor agonist, is a key copyrightple of this trend. To meet this demand, US-based manufacturing services are emerging. These providers offer